Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.